Predictive and prognostic significance of tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant systemic therapy

Anticancer Research

Volumn 34, Issue 3, 2014, Pages 1115-1125

  Melichar, Bohuslav ^a   Študentová, Hana ^a   Kalábová, Hana ^a   Vitásková, Denisa ^a   Čermáková, Petra ^b   Hornychová, Helena ^b   Ryška, Aleš ^b  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Breast cancer; Review; Targeted therapy; Tumor infiltrating lymphocytes

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; IMMUNOMODULATING AGENT; NEW DRUG; TRASTUZUMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOLOGY; DISEASE COURSE; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR DYNAMICS; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; SYSTEMIC THERAPY; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; ADJUVANT THERAPY; BREAST TUMOR; FEMALE; IMMUNOLOGY; PATHOLOGY; PROGNOSIS; TARGETED THERAPY; TUMOR-INFILTRATING LYMPHOCYTES;

BREAST CANCER; REVIEW; TARGETED THERAPY; TUMOR-INFILTRATING LYMPHOCYTES;

BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; NEOADJUVANT THERAPY; PROGNOSIS;

EID: 84899691817     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. DeSantis C, Ma J, Bryan L and Jemal A: Breast cancer statistics, 2013. CA Cancer J Clin 64: 52-62, 2014.
2. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL and Botstein D: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100: 8418-8423, 2003.
3. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL and Liu ET: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100: 10393-10398, 2003.
4. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC and O'Connell P: Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362: 362-369, 2003.
5. van de Vijver MJ, He YF, van't Veer LJ, Dai H, Hart AAM, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH and Bernards R: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009, 2002.
6. Melichar B: Laboratory medicine and medical oncology: The tale of two Cinderellas. Clin Chem Lab Med 51: 99-112, 2013.
7. Malyguine AM, Strobl SL and Shurin MR: Immunological monitoring of the tumor immunoenvironment for clinical trials. Cancer Immunol Immunother 61: 239-247, 2012.
8. Melichar B, Jandik P, Krejsek J, Solichova D, Drahosova M, Skopec F, Mergancova J and Voboril Z: Mitogen-induced lymphocyte proliferation and systemic immune activation in cancer patients. Tumori 82: 218-220, 1996.
9. Melichar B, Touskova M, Solichova D, Kralickova P and Kopecky O: CD4+ T-Lymphocytopenia and systemic immune activation in patients with primary and secondary liver tumours. Scand J Clin Lab Inv 61: 363-370, 2001.
10. Freedman RS, Vadhan-Raj S, Butts C, Savary C, Melichar B, Verschraegen C, Kavanagh JJ, Hicks ME, Levy LB, Folloder JK and Garcia ME: Pilot study of FLT3 ligand comparing intraperitoneal with subcutaneous routes on hematologic and, immunologic responses in patients with peritoneal carcinomatosis and mesotheliomas. Clin Cancer Res 9: 5228-5237, 2003.
11. Melichar B and Freedman RS: Immunology of the peritoneal cavity: Relevance for host-tumor relation. Int J Gynecol Cancer 12: 3-17, 2002.
12. Melichar B, Nash MA, Lenzi R, Platsoucas CD and Freedman RS: Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumor-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis. Clin Exp Immunol 119: 19-27, 2000.
13. Melichar B, Savary CA, Patenia R, Templin S, Melicharova K and Freedman RS: Phenotype and antitumor activity of ascitic fluid monocytes in patients with ovarian carcinoma. Int J Gynecol Cancer 13: 435-443, 2003.
14. Tomsova M, Melichar B, Sedlakova I and Steiner I: Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gyn Oncol 108: 415-420, 2008.
15. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlenger K, Liebman MN, Rubin SC and Coukos G: Intratumoral T-cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348: 203-213, 2003.
16. Yamagami W, Susumu N, Tanaka H, Hirasawa A, Banno K, Suzuki N, Tsuda H, Tsukazaki K and Aoki D: Immunofluorescence- detected infiltration of CD4+FOXP3+ regulatory Tcells is relevant to the prognosis of patients with endometrial cancer. Int J Gynecol Cancer 21: 1628-1634, 2011.
17. Ino K, Yamamoto E, Shibata K, Kajiyama H, Yoshida N, Terauchi M, Nawa A, Nagasaka T, Takikawa O and Kikkawa F: Inverse correlation between tumoral indoleamine-2,3- dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: Its association with disease progression and survival. Clin Cancer Res 14: 2310-2317, 2008.
18. Kondratiev S, Sabo E, Yakirevich E, Lavie O and Resnick MB: Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin Cancer Res 10: 4450-4456, 2004.
19. de Jong RA, Leffers HM, ten Hoor KA, van der Zee AGJ, Hollema H and Nijman HW: Presence of tumor-infiltrating lymphocytes is an independent prognosis factor in type I and II endometrial cancer. Gyn Oncol 114: 105-110, 2009.
20. Giatromanolaki A, Bates GJ, Koukourakis MI, Sivridis E, Gatter KC, Harris AL and Banham AH: The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer. Gyn Oncol 110: 216-221, 2008.
21. Menard S, Tomasic G, Casalini P, Balsari A, Pilotti S, Cascinelli N, Salvadori B, Colnaghi MI and Rilke F: Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res 3: 817-819, 1997.
22. Mohammed Z, Going JJ, Edwards J, Elsberger B, Doughty JC and McMillan DC: The relationship between components of tumor inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer. Br J Cancer 107: 864-873, 2012.
23. Loi S, Sirtaine N, Piette F, Sagado R, Viale G, Van Eenoo F, Rowas G, Francis P, Crown JPA, Hitre E, de Azambuja E, Quinaux E, Di Leo A, Michiels S, Piccart MJ and Sotiriou C: Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 31: 860-867, 2013.
24. Mahmoud SMA, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AHS, Ellis IO and Green AR: Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29: 1949-1955, 2011.
25. Topalian SL, Solomon D and Rosenberg SA: Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 142: 3714-3725, 1989.
26. Baxevanis CN, Dedoussis GVZ, Papadopoulos NG and Papamichail M: Tumor specific cytolysis by tumor-infiltrating lymphocytes in breast cancer. Cancer 74: 1275-1282, 1994.
27. Rosenberg SA, Spiess P and Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318-1321, 1986.
28. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP and White DE: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319: 1676-1680, 1988.
29. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG and White DE: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889-897, 1987.
30. Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, Ravoet M, Le Buanec H, Sibille C, Manfouo-Foutsop G, Veys I, Haibe-Kains B, Singhal SK, Michiels S, Rothe F, Salgado R, Duvillier H, Ignatiadis M, Desmedt C, Bron D, Larsimont D, Piccart M and Sotiriou C: CD4+ follicular helper T-cell infiltration predicts breast cancer survival. J Clin Invest 123: 2873-2882, 2013.
31. Hornychova H, Melichar B, Tomsova M, Mergancova J, Urminska H and Ryska A: Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma. Cancer Invest 26: 1024-1031, 2008.
32. Seo AN, Lee HJ, Kim EJ, Kim HJ, Jang MH, Lee HE, Kim YJ, Kim JH and Park SY: Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer 109: 2705-2713, 2013.
33. Dong DD, Yie S, K. L, Li F, Xu Y, Song L and Yang H: Importance of HLA-G expression and tumor infiltrating lymphocytes in molecular subtypes of breast cancer. Hum Immunol 73: 998-1004, 2012.
34. Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES and Coussens LM: Leukocyte composition of human breast cancer. Proc Natl Acad Sci USA 109: 2796-2801, 2012.
35. Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V, Biota C, Doffin AC, Durand I, Olive D, Perez S, Pasqual N, Faure C, Ray-Coquard I, Puisieux A, Caux C, Blay JY and Menetrier-Caux C: Regulatory T-cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 69: 2000-2009, 2009.
36. Cimino-Mathews A, Ye X, Meeker A, Argani P and Emens LA: Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: A pilot study. Human Pathol 44: 2055-2063, 2013.
37. Schmidt M, Hellwig B, Hammad S, Othman A, Lohr M, Chen Z, Boehm D, Gebhard S, Petry I, Lebrecht A, Cadenas C, Marchan R, Stewart JD, Solbach C, Holmberg L, Edlund K, Kultima HG, Rody A, Berglund A, Lambe M, Isaksson A, Botling J, Karn T, Mller V, Gerhold-Ay A, Cotarelo C, Sebastian M, Kronenwett R, Bojar H, Lehr HA, Sahin U, Koelbl H, Gehrmann M, Micke P, Rahnenführer J and Hengstler JG: A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin kappa C as a compatible prognostic marker in human solid tumors. Clin Cancer Res 18: 2695-2703, 2012.
38. Mulligan AM, Raitman I, Feeley L, Pinnaduwage D, Nguyen LT, O'Malley FP, Ohashi PS and Andrluis IL: Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancer from the Ontario Familial Breast Cancer Registry. Clin Cancer Res 19: 336-346, 2013.
39. Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM and Karin M: Fibroplast-recruited, tumorinfiltrating CD4+ T-cells stimulate mammary cancer metastasis through RANKL-RANK signaling. Nature 470: 548-553, 2011.
40. Martinet L, Garrido I, Filleron T, Guellec SL, Bellard E, Fournie JJ, Rochaix P and Girard JP: Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res 71: 5678-5687, 2011.
41. Martinet L, Filleron T, Guellec SL, Rochaix P, Garrido I and Girard JP: High endothelial venule blood vessels for tumorinfiltrating lymphocytes are associated with lymphotoxin betaproducing dendritic cells in human breast cancer. J Immunol 191: 2001-2008, 2013.
42. Melichar B, Ferrandina G, Verschraegen CF, Loercher A, Abbruzzese JL and Freedman RS: Growth-inhibitory effects of aromatic fatty acids on ovarian tumor cell lines. Clin Cancer Res 4: 3069-3076, 1998.
43. Jacquemier J, Bertucci F, Finetti P, Esterni B, Charafe-Jauffret C, Thibult ML, Houvenaeghel G, Van den Eynde B, Birnbaum D, Olive D and Xerri L: High expression of indoleamine-2,3- dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma. Int J Cancer 130: 96-104, 2012.
44. Yu J, Du W, Yan F, Wang Y, Li H, Cao S, Yu W, Shen C, Liu J and Ren X: Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol 190: 3783-3797, 2013.
45. Melichar B, Solichová D and Freedman RS: Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies. Int J Gynecol Cancer 16: 240-252, 2006.
46. Melichar B, Solichova D, Melicharova K, Malirova E, Cermanova M and Zadak Z: Urinary neopterin in patients with advanced colorectal carcinoma. Int J Biol Markers 21: 190-198, 2006.
47. Cincibuch J, Cwiertka K, Prochazkova-Studentova H, Zezulova M, Neoral C, Kalabova H, Krcmova L, Malirova E, Solichova D and Melichar B: Prognostic significance of serum neopterin in patients with esophageal carcinoma. Pteridines 23: 22-26, 2012.
48. Kalabova H, Krcmova L, Kasparova M, Plisek J, Laco J, Hyspler R, Klozova H, Solichova D and Melichar B: Prognostic significance of increased urinary neopterin concentrations in patients with breast carcinoma. Eur J Gynaecol Oncol 32: 525-529, 2011.
49. Sramek V, Melichar B, Studentova H, Kalabova H, Vrana D, Lukesova L, Adam T, Hlidkova E, Juranova J, Kujovska Krcmova L and Solichova D: Systemic immune response and peripheral blood cell count in patients with a history of breast cancer. Pteridines 24: 211-217, 2013.
50. Sramek V, Melichar B, Indrakova J, Studentova H, Kalabova H, Vrana D, Lukesova L, Adam T, Hlidkova E, Juranova J, Petrova P, Kujovska Krcmova L and Solichova D: Risk factors of atherosclerosis in patients with history of breast cancer. Pteridines 24: 201-210, 2013.
51. West NR, Milne K, Truong PT, Macpherson N, Nelson BH and Watson PH: Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res 13: R:126, 2011.
52. Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim SB, Pienkowski T, Lichinitser M, Semiglazov V, Melichar B and Jackisch C: Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): A phase III, open-label, multicentre, randomised trial. Lancet Oncol 13: 869-878, 2012.
53. Bear HD, Tang G, Rastogi P, Geyer CE, Robidoux A, Atkins JN, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Swain SM, Mamounas EP and Wolmark N: Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 366: 310-320, 2012.
54. von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggermann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Gerber B, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Fehm T, Muller BM, Denkert C, Loibl S, Nekljudova V and Untch M: Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 366: 299-309, 2012.
55. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW and Dimitrov NV: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15: 2483-2493, 1997.
56. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB, Hoehn JL, Lees AW, Dimitrov NV and Bear HD: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672-2685, 1998.
57. van der Hage JA, van de Velde CJH, Julien JP, Tubiana-Hulin M, Vandervelden C and Duchateau L: Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19: 4224-4237, 2001.
58. Mauri D, Pavlidis N and Ioannidis JPA: Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis. J Natl Cancer Inst 97: 188-194, 2005.
59. Chollet P, Amat S, Cure H, de Latour M, Le Bouedec G, Mouret-Reynier MA, Ferriere JP, Achard JL, Dauplat J and Penault-Llorca F: Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 86: 1041-1046, 2002.
60. Bear HD, Anderson S, Smith RE, Geyer CE, Mamounas EP, Fischer B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL and Wolmark N: Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project protocol B-27. J Clin Oncol 24: 2019-2027, 2006.
61. Machiavelli MR, Romero AO, Perez JE, Lacava JA, Dominguez ME, Rodriguez R, Barbieri MR, Acuna LAR, Acuna JMR, Langhi MJ, Amato S, Ortiz EH, Vallejo CT and Leone BA: Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 4: 125-131, 1998.
62. Thomas E, Holmes FA, Smith TL, Buzdar AU, Frye DK, Fraschini G, Singletary SE, Theriault RL, McNeese MD, Ames F, Walters R and Hortobagyi GN: The use of alternate, noncross- resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: Long-term results from a prospective randomized trial. J Clin Oncol 22: 2294-2302, 2004.
63. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchcholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN and Singletary SE: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17: 460-469, 1999.
64. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN and Pusztai L: Response to neoadjuvant therapy and long term survival in patients with triple negative breast cancer. J Clin Oncol 26: 1275-1281, 2008.
65. Prowell TM and Pazdur R: Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med 26: 2438-2441, 2012.
66. Chevallier B, Roche H, Olivier JP, Chollet P and Hurteloup P: Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in high histologic response rate. Am J Clin Oncol 16: 223-228, 1993.
67. Straver ME, Rutgers EJT, Rodenhuis S, Linn SC, Loo CE, Wesseling J, Russell NS, Oldenburg HSA, Antonini N and Vrancken Peeters MTFD: The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol 17: 2411-2418, 2010.
68. Bhargava R, Beriwal S, Dabbs DJ, Ozbek U, Soran A, Johnson RR, Brufsky AM, Lembersky BC and Ahrendt GM: Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy. A single institutional experience with 358 cases. Cancer 116: 1431-1439, 2010.
69. Tan MC, Al Mushawah F, Gao F, Aft RL, Gillanders WE, Eberlein TJ and Margenthaler JA: Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer. Am J Surg 198: 520-525, 2009.
70. Montagna E, Bagnardi V, Rotmensz N, Viale G, Pruneri G, Veronesi P, Cancello G, Balduzzi A, Dellapasqua S, Cardillo A, Luini A, Zurrida S, Gentilini O, Mastropasqua MG, Bottiglieri L, Iorfida M, Goldhirsch A and Colleoni M: Pathological complete response after preoperative systemic therapy and outcome: Relevance of clinical and biologic baseline features. Breast Cancer Res Treat 124: 689-699, 2010.
71. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML and Perou CM: The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13: 2329-2334, 2007.
72. Melichar B, Hornychova H, Kalabova H, Basova H, Mergancova J, Urminska H, Jandik P, Cervinka V, Laco J and Ryska A: Increased efficacy of a dose-dense regimen of neoadjuvant chemotherapy in breast carcinoma: A retrospective analysis. Med Oncol 29: 2577-2585, 2012.
73. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D and Hortobagyi GN: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23: 3676-3685, 2005.
74. Melichar B, Urbanek L, Krcmova L, Kalabova H, Melicharova K, Malirova E, Hornychova H, Ryska A, Hyspler R and Solichova D: Urinary neopterin, hemoglobin and peripheral blood cell counts in breast carcinoma patients treated with dosedense chemotherapy. Anticancer Res 28: 2389-2396, 2008.
75. Melichar B, Touskova M, Dvorak J, Jandik P and Kopecky O: The peripheral blood leukocyte phenotype in patients with breast cancer: Effect of doxorubicin/paclitaxel combination chemotherapy. Immunopharmacol Immunotoxicol 23: 163-173, 2001.
76. Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, Buczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, von Torne C, Weichert W, Engels K, Solbach C, Schrader I, Dietel M and von Minckwitz G: Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28: 105-113, 2010.
77. Yamaguchi R, Tanaka M, Yano A, Tse GM, Yamaguchi M, Koura K, Kanomata N, Kawaguchi A, Akiba J, Kanomata N, Kawaguchi A, Akiba J, Naito Y, Ohshima K and Yano H: Tumorinfiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer. Hum Pathol 43: 1688-1694, 2012.
78. Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H, Hirata T, Yenemori K, Ando M, Tamura K, Katsumata N, Kinoshita T, Takiguchi Y, Tanzawa H and Fujiwara Y: Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat 132: 793-805, 2012.
79. Oda N, Shimazu K, Naoi Y, Morimoto K, Shimomura A, Shimoda M, Kagara N, Maruyama N, Kim SJ and Noguchi S: Intratumoral regulatory T-cells as an indepedent predictive factor pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin/ cyclophosphamide in breast cancer patients. Breast Cancer Res Treat 136: 107-116, 2012.
80. Issa-Nummer Y, Darb-Esfahani S, Loibl S, Kunz G, Nekljudova V, Schrader I, Sinn BV, Ulmer HU, Kronenwett R, Just M, Kuhn T, Diebold K, Untch M, Holms F, Blohmer JU, Habeck JO, Dietel M, Overkamp F, Krabisch P, von Minckwitz G and Denkert C: Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2- negative breast cancer - a substudy of the neoadjuvant GeparQuinto trial. PLoS One 8: e79775, 2013.
81. Demaria S, Volm MD, Shapiro RL, Yee HT, Oratz R, Formenti SC, Muggia F and Symmans WF: Development of tumorinfiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res 7: 3025-3030, 2001.
82. Ladoire S, Arnould L, Apetoh L, Coudert B, Martin F, Chauffert B, Fumoleau P and Ghiringhelli F: Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating FOX3+ regulatory T-cells. Clin Cancer Res 14: 2413-2420, 2008.
83. Ladoire S, Mignot G, Dabakuyo S, Arnould L, Apetoh L, Rebe C, Coudert B, Martin F, Bizollon MH, Vanoli A, Coutant C, Fumoleau P, Bonnetain F and Ghiringhelli F: In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol 224: 389-400, 2011.
84. Liu F, Li Y, Ren M, Zhang X, Guo X, Lang R, Gu F and Fu L: Peritumoral FOXP3+ regulatory T-cell is sensitive to chemotherapy, while intratumoral FOXP3+ regulatory T-cell is prognostic predictor of breast cancer patients. Breast Cancer Res Treat 135: 459-467, 2012.
85. Aruga T, Suzuki E, Saji S, Horiguchi SI, Horiguchi K, Sekine S, Kitagawa D, Funata N, Toi M, Sugihara K and Kuroi K: A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable antitumor response in patients with breast cancer. Oncol Rep 22: 273-278, 2009.
86. West NR, Kost SE, Martin SD, Milne K, deLeeuw BH, Nelson BH and Watson PH: Tumour-infiltrating FOXP3+ lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. Br J Cancer 108: 155-162, 2013.
87. Ma C, Zhang Q, Ye J, Wang F, Zhang Y, Wevers E, Schwartz T, Humborg P, Varvares MA, Hoft DF, Hsueh EC and Peng G: Tumor-infiltrating γδ T-lymphocytes predict clinical outcome in human breast cancer. J Immunol 189: 5029-5036, 2012.
88. Muenst S, Soysal SD, Obermann EC, Oertli D and Gillanders WE: The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 139: 667-676, 2013.
89. Valabrega G, Montemurro F and Aglietta M: Trastuzumab: mechanism of action, resistance and future perspectives in HER2- overexpressing breast cancer. Ann Oncol 18: 977-984, 2007.
90. Hudis CA: Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 357: 39-51, 2007.
91. Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Garnier J, Jeannin JF and Coudert B: Trastuzumab-based treatment of HER2-positive breast cancer an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 94: 259-267, 2006.
92. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, Neri TM and Ardizzoni A: Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER2/neu-positive metastatic breast cancer. J Clin Oncol 26: 1789-1796, 2008.
93. Gabrilovich DI, Chen HL, Girgis KR, Cunningham T, Meny GM, Nadaf S, Kavanaugh D and Carbone DP: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2: 1096-1103, 1996.
94. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chern L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM and Sznol M: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2455-2465, 2012.